TWO · 1780.TWO
Allied Biotech Corporation
NT$23.95-NT$0.10 (-0.42%)
Allied Biotech Corporation’s quoted price sits in the lower half of its reported 52-week range, 35.01% below the high.
Loading market information…
TAI · 3054.TW · TWD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
LIWANLI Innovation Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 40.63% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
LIWANLI Innovation Co., Ltd.’s forward annual dividend is NT$0.54 per share, paid annual. The forward yield is 0.94% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow LIWANLI Innovation Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
LIWANLI Innovation Co., Ltd. operates within the biomedical science sector, concentrating on the development and distribution of nutrition and healthcare solutions. The company's diverse product portfolio, which notably features the Vigoway line and various powdered formulations, is designed to serve a wide range of consumers, including men, women, seniors, and children. Its extensive offerings encompass products such as probiotic enzymes, active nutrients, resveratrol red grape extract, and a variety of soft gels (including those with algae DHA, shea butter with type II collagen, and algae astaxanthin Q10). Other specialized items include cordyceps militaris powder, tooth guard tablets, bovine and goat's milk bites, bilberry tablets, and DHA and vitamin D3 drops, among others. The firm was formerly known as Carry Technology International Co., Ltd. before officially adopting its current name, LIWANLI Innovation Co., Ltd., in 2015. Established in 1980, the company's headquarters are located in New Taipei City, Taiwan.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:28 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$23.95-NT$0.10 (-0.42%)
Allied Biotech Corporation’s quoted price sits in the lower half of its reported 52-week range, 35.01% below the high.
NT$55.70+NT$0.80 (+1.46%)
TSH Biopharm Corporation Limited’s quoted price sits in the upper half of its reported 52-week range, 6.07% below the high.
NT$44.20+NT$1.35 (+3.15%)
BenQ Medical Technology Corporation’s quoted price sits in the upper half of its reported 52-week range, 11.42% below the high.
NT$31.45+NT$0.55 (+1.78%)
DIVA Laboratories, Ltd.’s quoted price sits in the lower half of its reported 52-week range, 16.8% below the high.
NT$72.10-NT$0.40 (-0.55%)
Crystalvue Medical Corporation’s quoted price sits in the lower half of its reported 52-week range, 13.45% below the high.
NT$57.80-NT$0.60 (-1.03%)
Greenyn Biotechnology Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 25.9% below the high.
NT$9.88-NT$0.06 (-0.6%)
InnoPharmax Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.4% below the high.
NT$27.25-NT$0.55 (-1.98%)
GeneFerm Biotechnology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 48.1% below the high.
